This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
3 Reasons Why Amedisys (AMED) Is a Great Growth Stock
by Zacks Equity Research
Amedisys (AMED) possesses solid growth attributes, which could help it handily outperform the market.
Amedisys (AMED) Beats Q3 Earnings Estimates, Ups 2020 View
by Zacks Equity Research
An impressive Q3 performance by Amedisys' (AMED) Home health and hospice amid the pandemic-led business disruptions buoys optimism.
Amedisys (AMED) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 76.38% and 2.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
by Zacks Equity Research
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
Pick These 5 Stocks With Superb Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS), Amedisys (AMED) and Insperity (NSP) are sound enough to meet financial obligations.
Amedisys (AMED) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is Amedisys (AMED) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.
Amedisys (AMED) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 69.62% and 4.30%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amedisys (AMED) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys Rides on Coronavirus-Led Business Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.
Why the Earnings Surprise Streak Could Continue for Amedisys (AMED)
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ADUS vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?
Healthcare for Silver Years to Aid Encompass Health (EHC)
by Zacks Equity Research
Encompass Health's (EHC) inpatient rehabilitation and home hospice businesses are poised to grow on the back of aging population.
Amedisys Rides on Hospice Arm Expansion Amid Coronavirus Woes
by Zacks Equity Research
Amedisys (AMED) benefits from the recent acquisitions of hospice care providers, Asana Hospice, RoseRock Healthcare and Compassionate Care Hospice.
DGX vs. AMED: Which Stock Is the Better Value Option?
by Zacks Equity Research
DGX vs. AMED: Which Stock Is the Better Value Option?
Here's Why You Should Add Ensign Group to Your Portfolio
by Zacks Equity Research
Strategic initiatives and a healthy balance sheet make Ensign Group (ENSG) an attractive pick for investors.
Amedisys (AMED) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Broadens Hospice Base With AseraCare Buyout
by Zacks Equity Research
Amedisys (AMED) expects AseraCare business to add greater scale to its existing nationwide network.
Hospital Industry's Dull Near-Term Outllook Induced by Coronavirus
by Sapna Bagaria
Revenue loss and cost rise due to coronavirus outbreak put hospital companies in a tight spot.